Keyphrases
Treatment Algorithm
100%
End-stage Renal Disease
100%
Radiopharmaceuticals
100%
Lutetium-177 (177Lu)
100%
Peptide Receptor Radionuclide Therapy
100%
Neuroendocrine Tumor
40%
Adjusted Dose
40%
Maintenance Hemodialysis Patients
40%
Yttrium-90
20%
North America
20%
Renal Function
20%
Radioligand
20%
Serious Adverse Events
20%
Hemodialysis
20%
Hemodialysis Patients
20%
Multidisciplinary Groups
20%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
20%
Testing Data
20%
Received Dose
20%
Neuroendocrine Neoplasms
20%
Pharmacokinetic Evaluation
20%
Advanced Kidney Disease
20%
DOTATATE
20%
Early Testing
20%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
100%
End Stage Renal Disease
100%
Radioisotope
100%
Lutetium 177
100%
Hemodialysis
80%
Neuroendocrine Tumor
60%
Adverse Event
20%
Radioligand
20%
Kidney Disease
20%
Castration Resistant Prostate Cancer
20%
Pharmacokinetics
20%